PhaseRx, Inc.
PZRXQ · OTC
12/31/2016 | 12/31/2015 | 12/31/2014 | |
|---|---|---|---|
| Valuation | |||
| PEG Ratio | -0.00 | 0.28 | 0.00 |
| FCF Yield | -85.59% | -15.40% | -16.61% |
| EV / EBITDA | -0.41 | -10.40 | -8.07 |
| Quality | |||
| ROIC | -122.20% | 3,356.65% | 705.04% |
| Gross Margin | 0.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.49 | 0.81 | 0.71 |
| Growth | |||
| Revenue 3-Year CAGR | -100.00% | 721,024.79% | 1,062,558.57% |
| Free Cash Flow Growth | -63.80% | -24.01% | 0.00% |
| Safety | |||
| Net Debt / EBITDA | 0.24 | -3.07 | -2.11 |
| Interest Coverage | -8.91 | -3.52 | -4.09 |
| Efficiency | |||
| Inventory Turnover | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 |